540222
Puromycin, Dihydrochloride
Puromycin, Dihydrochloride, CAS 58-58-2, is An aminonucleoside antibiotic that inhibits protein synthesis by blocking the translation step and causes premature release of nascent polypeptide chains.
Synonym(s):
Puromycin, Dihydrochloride
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C22H29N7O5 · 2HCl
CAS Number:
Molecular Weight:
544.43
UNSPSC Code:
12352200
MDL number:
Quality Level
assay
≥98% (TLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, desiccated
color
white to off-white
solubility
methanol: 20 mg/mL, water: 50 mg/mL
shipped in
ambient
storage temp.
−20°C
InChI
1S/C22H29N7O5.2ClH/c1-28(2)19-17-20(25-10-24-19)29(11-26-17)22-18(31)16(15(9-30)34-22)27-21(32)14(23)8-12-4-6-13(33-3)7-5-12;;/h4-7,10-11,14-16,18,22,30-31H,8-9,23H2,1-3H3,(H,27,32);2*1H/t14-,15+,16?,18+,22+;;/m0../s1
InChI key
MKSVFGKWZLUTTO-USYAMCSGSA-N
General description
Prokaryotic and eukaryotic protein synthesis inhibitor. Nucleoside that resembles the aminoacyl-adenylyl terminus of aminoacyl-tRNA and competes for binding to the "A site" of the large ribosomal subunit. Its incorporation into a growing polypeptide results in termination of chain elongation and release of the nascent polypeptidyl-puromycin. Used for selection of mammalian cell lines expressing a transfected pac gene (Streptomyces alboniger), whose product, puromycin acetyltransferase, inactivates the drug via acetylation. Induces DNA fragmentation in thymocytes and in human HL-60 leukemia cells. Like cycloheximide, puromycin is also used as a general protein synthesis inhibitor in numerous cellular assays.
Protein synthesis inhibitor. Inhibits translation by causing premature release of nascent polypeptide chains. Induces DNA fragmentation in thymocytes and in human HL-60 leukemia cells.
Puromycin, Dihydrochloride, CAS 58-58-2, is An aminonucleoside antibiotic that inhibits protein synthesis by blocking the translation step and causes premature release of nascent polypeptide chains.
Biochem/physiol Actions
Primary Target
protein synthesis
protein synthesis
Preparation Note
Following reconstitution, sterilize by filtration through a 0.22 µm pore-size filter, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Chow, S.C., et al. 1995. Exp. Cell Res. 216, 149.
Constam, D.B., et al. 1995. J. Biol. Chem.270, 26931.
Wirth, M., et al. 1994. J. Virol.68, 566.
Claeyssens, S., et al. 1993. FEBS Lett.315, 7.
Hechler, U., et al. 1993. Biochem. Biophys. Res. Commun.194, 1305.
Kaufman, S.H., et al. 1993. Cancer Res.53, 3976.
de la Luna, S. and Ortín, J. 1992. Methods Enzymol.216, 376.
Kalpaxis, D.L. and Drainas, D. 1992. Arch. Biochem. Biophys.300, 629.
Shipston, M.J. and Antoni, F.A. 1992. Biochem. Biophys. Res. Commun.189, 1382.
Constam, D.B., et al. 1995. J. Biol. Chem.270, 26931.
Wirth, M., et al. 1994. J. Virol.68, 566.
Claeyssens, S., et al. 1993. FEBS Lett.315, 7.
Hechler, U., et al. 1993. Biochem. Biophys. Res. Commun.194, 1305.
Kaufman, S.H., et al. 1993. Cancer Res.53, 3976.
de la Luna, S. and Ortín, J. 1992. Methods Enzymol.216, 376.
Kalpaxis, D.L. and Drainas, D. 1992. Arch. Biochem. Biophys.300, 629.
Shipston, M.J. and Antoni, F.A. 1992. Biochem. Biophys. Res. Commun.189, 1382.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Harmful (C)
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
涉药品监管产品
This item has
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Rui Chen et al.
BMC medicine, 20(1), 68-68 (2022-02-17)
Genome-wide association studies (GWASs) have identified multiple risk loci for Parkinson's disease (PD). However, identifying the functional (or potential causal) variants in the reported risk loci and elucidating their roles in PD pathogenesis remain major challenges. To identify the potential
Rui Chen et al.
Genome medicine, 14(1), 53-53 (2022-05-20)
Genome-wide association studies (GWASs) have identified multiple risk loci for bipolar disorder (BD). However, pinpointing functional (or causal) variants in the reported risk loci and elucidating their regulatory mechanisms remain challenging. We first integrated chromatin immunoprecipitation sequencing (ChIP-Seq) data from
Ying Huang et al.
Frontiers in physiology, 12, 697139-697139 (2021-09-08)
Our previous study found that acupuncture with low frequency electrical stimulation (Acu/LFES) prevents muscle atrophy by attenuation of protein degradation in mice. The current study examines the impact of Acu/LFES on protein synthesis. C57/BL6 mice received Acu/LFES treatment on hindlimb
Global Trade Item Number
| SKU | GTIN |
|---|---|
| 540222-100MG | 04055977268768 |
| 540222-25MG | 07790788051396 |